Filligent has received 510k approval from the U.S. Food and Drug Administration for its BioFriend BioMask (series A), which is an anti-viral surgical facemask, according to a company news release.
The BioFriend BioMask reduces the bio-burden of germs on the mask, effectively reducing the wearer's exposure to germs and reducing the risk of healthcare-associated infections. Additionally, in independent laboratory tests, the BioFriend BioMask facemask inactivated 99.99 percent of tested pandemic and seasonal strains of influenza A and B viruses in five minutes.
Read the company news release about BioFriend BioMask.
Contrast Agent Could Help Detect Infections Through Imaging
Study: MRSA Bundle Implementation Needs the Right Multidisciplinary Team
The BioFriend BioMask reduces the bio-burden of germs on the mask, effectively reducing the wearer's exposure to germs and reducing the risk of healthcare-associated infections. Additionally, in independent laboratory tests, the BioFriend BioMask facemask inactivated 99.99 percent of tested pandemic and seasonal strains of influenza A and B viruses in five minutes.
Read the company news release about BioFriend BioMask.
Related Articles on Infection Control:
Survey: 64% of Americans Don't Believe They're Safer From Germs in a HospitalContrast Agent Could Help Detect Infections Through Imaging
Study: MRSA Bundle Implementation Needs the Right Multidisciplinary Team